Reducing Anticholinergic Medications in Schizophrenia
Part of Mental health clinical trials.
This trial is testing whether it is safe to slowly reduce or stop anticholinergic medications (benztropine or trihexyphenidyl) in people with schizophrenia. It aims to see if stopping these drugs can help with thinking and memory without causing worsening movement problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of schizophrenia, schizoaffective disorder, or a related psychotic disorder, confirmed by a doctor.
- You must be taking benztropine or trihexyphenidyl (medications for antipsychotic side effects) for at least 6 months.
- You must be between 35 and 70 years old.
- You should not have serious side effects from the anticholinergic medication, like fever or blurry vision.
- You cannot have a neurological condition like Parkinson's disease, dementia, multiple sclerosis, lupus, or a history of traumatic brain injury.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses PET and MRI scans to see how antipsychotic medications affect the brain's dopamine system in people with schizophrenia, compared to healthy individuals. It may help understand if these medications cause changes that lead to worsening symptoms over time.
This Phase 2 trial tests whether a “synbiotic” supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia or schizoaffective disorder. It may help by targeting gut-related immune and inflammation pathways that could affect brain symptoms.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This study looks at how a specific type of brain receptor (dopamine-3) works in people with schizophrenia using special brain scans (PET). Researchers want to see how these receptors behave when you are not taking antipsychotic medication, which may help guide future treatments.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.